New review links higher nut intake with lower hypertension risk
A dose–response analysis of prospective studies found lower risk at higher nut intake, with “probable” likelihood of causality by WCRF criteria.
High evidenceReview
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
In this updated analysis, the authors searched PubMed and Embase for prospective cohort studies published in English up to April 4, 2026. They included eight studies with a total of 20,665 cases and extracted adjusted risk estimates for the relationship between nut consumption and hypertension.
Overall, the meta-analysis reported lower hypertension risk with higher nut intake. The authors also assessed bias and evidence strength using WCRF criteria and graded the likelihood of causality as “probable.” Some nonlinear patterns and between-study differences were noted, which the authors considered in interpreting the results.
The question reviewed
The researchers examined whether nut consumption is associated with the risk of developing hypertension. They used a systematic review and dose–response meta-analysis of prospective cohort studies, including studies that reported adjusted relative risk estimates (published in English) and were found via PubMed and Embase searches up to 4 April 2026. The meta-analysis included eight studies (20,665 cases, with the abstract listing “x” for the remaining figure as unknown).
Key conclusions
Across included prospective studies, the summary relative risk (RR) for the highest versus lowest category of nut intake was 0.84 (95% CI: 0.77–0.91), with I² = 50% and p heterogeneity = 0.05. For the dose–response comparison, the RR per 28 g/day was 0.80 (95% CI: 0.71–0.89), with I² = 75% and p heterogeneity < 0.0001. The authors reported no indication of publication bias using Begg’s test (p = 0.71), Egger’s test (p = 0.10), or funnel plot inspection. They noted some indication of nonlinearity (p nonlinearity = 0.07), and described a 26% reduction in risk for 30 g/day versus 0 g/day. Using WCRF criteria, they graded the likelihood of causality as “probable.”
Who this is relevant to
These findings may be most applicable to people in populations similar to those studied in the included English-language prospective cohort studies that measured nut intake and assessed hypertension risk. They do not directly establish that increasing nut intake will cause lower hypertension risk for any specific person, because observational studies cannot fully rule out other factors. This work is not a clinical trial and does not provide personalized guidance; it only summarizes associations reported across multiple studies.
What this could mean
Hypertension is a common health condition, so evidence about dietary factors associated with its risk is of broad public interest. This study is a review of prospective human data, so it is more directly relevant to general human health than animal or lab findings. Even so, because the included studies are observational, the results reflect an association rather than proof that nut intake directly causes lower hypertension risk in individuals.
Limitations & evidence assessment
The analysis is based on prospective cohort studies, which can still be affected by confounding and measurement differences in how nut intake and hypertension were assessed. The abstract does not provide key details about populations, follow-up duration, how nut intake categories were defined, or which nut types were included, limiting how precisely readers can interpret the dose–response relationship. There was moderate to high heterogeneity (I² up to 75%), suggesting results varied across studies. The abstract notes some indication of nonlinearity and does not fully characterize its practical meaning. The abstract also contains an incomplete numeric detail (“x”) for included studies, so the full context of the included-case reporting is unclear from the provided text.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
British Journal Of Nutrition · 2026 · DOI: 10.1017/s0007114526108137
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
